See Beyond the Lumen
Deliver personalized patient care with the only histologically-validated, objective and quantitative CTA-based arterial analysis software.
Clinical Problem
Misdiagnosed Myocardial Ischemia, Heart Attack & Stroke Risk Leads to Poor Outcomes
Myocardial ischemia occurs when blood flow to your heart is reduced, preventing the heart muscle from receiving enough oxygen. This is often the result of plaque buildup inside the artery wall.
Heart attack and stroke are primarily caused by non-obstructive, but unstable plaque in the arteries that goes undiagnosed and untreated.1 Current non-invasive testing cannot visualize the biology deep inside artery walls where heart disease develops.
Elucid is harnessing scientific imaging and histology to help enable quick, accurate, noninvasive diagnoses and precise treatment of cardiovascular disease to enable better patient outcomes.
Solution
Accurate Clinical Insights Based on Biology
Introducing the first and only non-invasive image analysis software that employs CT angiography and patented computer algorithms, based on expert histologic examination of thousands of tissue samples and images, to objectively quantify the extent and stability of arterial plaque for tailored patient care.
Technology backed by 40+ years of clinical research
Powerful. Precise. Proven.
87%
Accurate prediction of major adverse cardiac events2*
40%
Better Stroke Prediction3*
Elucid PlaqueIQ Comprehensive
Healthcare Solutions
- Assess plaque composition with histology-validated software
- Quantify plaque to inform heart attack and stroke risk with greater accuracy
- Visualize a comprehensive and objective view of arterial disease to enable personalized treatment plans before a patient ever enters the hospital
- Understand your risk of heart attack and stroke
- Receive safe and accurate non-invasive diagnostic testing
- Experience personalized treatment plans
- Early detection for improved clinical care and consistent outcomes
- Reduce unnecessary invasive testing, lowering cost of care
- Enables physicians to identify asymptomatic high-risk patients who may have otherwise gone untreated
- Help identify promising drug candidates with greater speed and accuracy
- May reduce clinical trial size, costs and timelines by stratifying high-risk patients
- If you are interested in submitting a proposal for a research study, click here.
PlaqueIQ™ Technology
Translate CTA into Scientific Images in 2 Steps
Accurately restore vessel structure and plaque morphology, including lipid rich necrotic core:
Image Processing
The only CTA-based plaque assessment rigorously validated with histopathology*
Based on expert analysis of microscopic tissue samples by world-renowned cardiovascular pathologists.
- Lipid-Rich Necrotic Core
- Calcification
- Intraplaque Hemorrhage*
- Matrix
- Fibrous Cap/Perivascular Adipose Tissue*
*Available in Elucid PlaqueIQ Research Edition only.
The Elucid algorithms demonstrate excellent correlation and are highly accurate for tissue characterization when compared to ex vivo histopathology.”
Secure, Workflow-Oriented Technology
News
Elucid Adds Clinical and Commercial Leadership Ahead of PlaqueIQ™ Launch
BOSTON – March 3, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added several senior members to its clinical and commercial teams. The...
Elucid Announces CCTA Reimbursement to be Doubled with CMS Rule
Decision makes crucial cardiovascular imaging and CT-based technologies more economically viable to hospital outpatient and ambulatory care providers BOSTON – November 4, 2024 – Elucid Bioimaging, Inc. has announced a final rule from US Centers for Medicare &...
Elucid Announces Fifth Medicare Administrative Contractor to Cover AI Coronary Plaque Analysis
Noridian latest MAC to make Elucid PlaqueIQTM image analysis software available for eligible patients BOSTON – October 25, 2024 – Elucid has announced that Noridian will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared...
About
Bringing Imaging to Life™
Our mission is to provide comprehensive and accurate clinical insights based on ground-truth histology, enabling unprecedented precision healthcare for vascular disease. Contact us today to learn more about Elucid clinical solutions:
Our Portfolio
Elucid PlaqueIQ
FDA-cleared, non-invasive CTA analysis software providing unprecedented specificity of plaque stability and vessel structure, based on histology.
Elucid FFRCT + PlaqueIQ
Combination of plaque analysis, based on histology, and FFR for a more direct measure of stress induced ischemia while characterizing plaque risk. Coming Soon!
Elucid Clinical Research
CTA analysis software with innovative additional features for clinical research and studies.
Elucid Leadership
Kelly Huang, PhD
President & CEO
Blake Richards
Chief Operating Officer
Andrew Miller
Chief Technology Officer & SVP, Engineering
Windi Hary
Chief Regulatory & Quality Officer
Sophie Khem
SVP, Clinical Quality & Delivery
Amy Kruglak
SVP, People & Leadership Development
Kevin Mathews
SVP, Marketing
Amir Ahmadi, MD
Chief Scientific Advisor
Partners
Elucid is used to help evaluate patient outcomes, safety and clinical efficacy in clinical trials with industry partners, including:
Contact
Contact us today to learn more about Elucid or to schedule a product demo.
Boston, MA 02116
